Blood tests for Alzheimer’s disease are now so accurate that a positive result, on its own, is reason enough for people who are suspected of having AD to start immunotherapy. So proffered Suzanne ...

At this year’s Alzheimer’s Association International Conference, held July 27-31 in Toronto, scientists introduced a plethora of new assays for biomarkers that could improve diagnosis and tracking of ...

The Dominantly Inherited Alzheimer Network has been at the vanguard of AD immunotherapy development, launching the first secondary and primary prevention trials, as well as the first study of ...

GNPC has assembled proteomic data on 40,000 blood and CSF samples from cohorts of neurodegenerative disease. The dataset will be released for public use July 15. GNPC scientists are adding more ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

On September 26, 2024, the National Institute on Aging (NIA) announced that Masliah had been removed from his position as scientific director of the institute’s neuroscience division after a ...

As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association ...

A new multiplex diagnostic method appears poised to resculpt the biomarker landscape. NULISA, aka NUcleic acid Linked Immunosorbent Assay, can detect Aβ peptides, p-tau isoforms, and other potential ...

The two new deaths seem to be of the third category. At baseline, the APOE4 homozygote at Columbia had one microhemorrhage on MRI, and no signs of CAA, and appeared to be a good candidate for the ...